glp-1 agonist history Receptor Market Growth Analysis Trends in the Development of
Description
Incorporating considerations of resources use into grading recommendations
Our clinical experience has taught us that most patients tolerate the medications well the proper dosing protocols in place and proper management of adverse effects
Dual inhibition of the renin-angiotensin system in high-risk diabetes and risk for stroke and other outcomes: results of the ONTARGET trial
GLP-1 drugs, originally designed for diabetes, now show solid results in helping people lose weight
Occurrence of gastrointestinal adverse events upon GLP-1 receptor agonist initiation with concomitant metformin use: A post hoc analysis of LEADER, STEP 2, SUSTAIN-6, and PIONEER 6
PMID: 38639975.
